1. Introduction
Enterococcus faecalis (E. faecalis) is a Gram-positive, facultative anaerobic bacterium, which almost serves as normal colonizing bacteria in the gastrointestinal tracts of humans and is generally related to commensal life in the gastrointestinal tract [1]. E. faecalis has strong environmental adaptability. The abilities to form robust and mature biofilms [2,3,4] makes E. faecalis able to survive in scarce nutrition and resist extreme alkaline pH values [5,6,7,8]. With biofilm formation, E. faecalis can also cause serious infection. As one of the most common pathogens in hospital infections, E. faecalis leads to various opportunistic infections [9,10,11,12,13] such as urinary tract infections, bacteremia, prosthetic joint infections, abdominal-pelvic infections, endocarditis [14,15,16], periodontal disease, and endodontic infections [17,18]. Despite its pathogenicity, E. faecalis is also a probiotic and is often found as part of the autochthonous flora in a variety of fermented foods, namely cheeses and sausages [19,20,21,22,23].
Among the regulatory systems in E. faecalis [24], the two-component signal transduction system (TCS) is one of the signal pathways necessary for bacteria to adapt to the environmental changes, which helps bacteria to perceive and respond to external signals rapidly. A TCS consists of two basic components: histidine kinase (HK), which is anchored to the cell membrane, and intracellular response regulators (RRs). The HK responds to the environmental stimulus by auto-phosphorylating on a conserved histidine residue in the cytoplasmic domain. Then, the phosphate group is transferred to an aspartate residue on the partner RR. Through affinity for target promoter DNA, RR effects a corresponding modulation of transcription and elicits a cellular response to the environmental stimuli [25,26].
E. faecalis includes 17 members of two-component systems, in which the CroRS system is required for intrinsic β-lactam resistance [27,28]. The β-lactams are structural analogs of the D-Ala4-D-Ala5, an extremity of peptidoglycan precursors, and act as suicide substrates of the D, D-transpeptidases that catalyze the last cross-linking step of peptidoglycan synthesis [29]. The CroS HK activates in response to the cell wall damage induced by antimicrobial effects, and CroR upregulates an alternative penicillin-binding protein (PBP), carrying out transpeptidase activity with a low-binding affinity for β-lactams [30]. By enhancing the release of nucleic acids into the biofilm matrix, the two-component Fsr-QS (quorum sensing) system controls the production of extracellular gelatinase and contributes to the biofilm formation [31]. The fsr regulatory locus is comprised of three genes, designated as FsrA, FsrB, and FsrC, which are necessary for positive regulation of the virulence-associated proteases Gelatinase E (GelE) and serine protease (SprE) [32,33]. FsrC is a histidine kinase that senses extracellular accumulation of a peptide lactone encoded at the C-terminus of the FsrB protein. The sensing of FsrC leads to activation of the response regulator and transcription factor FsrA [34]. In addition, the Fsr system positively regulates degradation of important immunopeptides, exerts an inhibitory effect against the complement system, and performs a critical role in overcoming the immune systems that are inherent to human serum [34,35,36]. Glycopeptide antibiotics vancomycin (VM) and teicoplanin (TE) inhibit the extracellular steps of bacterial peptidoglycan synthesis by binding to the C-terminal D-alanyl-D-alanine (D-Ala-D-Ala) residues of cell wall precursors. Synthesis of modified peptidoglycan precursors terminating in D-lactate, glycopeptide such as peptidoglycan precursor UDP-N-acetylmuramyl-L-Ala-γ-D-Glu-L-Lys-D-Ala-D-lactate (UDP-MurNAc-pentadepsipeptide) makes a more than 1000-fold decreased affinity for glycopeptides resistance. In E. faecalis, the TCS VanSRB regulates an immediately downstream promoter and contributes to VanB-type vancomycin resistance. Vancomycin is identified as an inducer for the VanSBRB activation [27,37]. Among all 17 TCSs, walRK is the only essential TCS for E. faecalis, which determines the viability of stains, indicating that the survival of bacteria can be significantly affected by the knockout of walRK [26].
The WalRK (also named YycFG or VicRK) TCS signaling pathway is one of the most widely distributed TCS systems, highly conserved in most low-G+C Gram-positive bacteria [38]. The system has been reported as necessary for several closely related pathogens including Staphylococcus aureus [39], Streptococcus pneumoniae [40], and Bacillus subtilis [41]. The core of the WalRK TCS consists of HK (WalK) on the cell surface and an intracellular RR (WalR) [25]. The WalK histidine kinases contain HAMP (a domain present in histidine kinases, adenylyl cyclases, methyl-accepting proteins, and phosphatases) and PAS (Per-Arnt-Sim) sensing domains, which promote two-way conformational communication between the input and output domains signaling proteins, along with histidine phosphotransfer (HisKA) and kinase catalytic (HATPase) domains [42,43,44,45]. The amino acid sequences of the receiver and effector domains of WalR are highly conserved and belong to the OmpR family of response regulators [44,45,46]. In addition to walR and walK, yycH, yycI, and yycJ are also included in the E. faecalis WalRK TCS [47,48]. The auxiliary proteins YycHI play roles in signaling through the WalK [45]. Although the cytoplasmic, conserved YycJ auxiliary protein contains a putative metal binding site in a β-lactamase fold [49], its functions are currently unknown [45]. In this review, we investigate the role of the WalRK system in the metabolism of E. faecalis, including biofilm formation, cell wall construction, drug resistance, and resistance to the host immune system. In addition, potentially therapeutic strategies associated with the WalRK TCS are noted for clinical infections administration.
2. Material and Methods
Based on searching the PubMed database with terms “WalR, WalK, two-component system, Enterococcus faecalis, regulation, and treatment”, we conduct a literature search. The inclusion criteria included: (1) original studies or reviews on related topics; (2) published in English; (3) full-text. The exclusion criteria included: (1) abstracts from conferences and (2) document cannot be downloaded. The search in PubMed yielded 426 articles and, after exclusion, 122 were included in our literature manager. To supply our possibly ignored information, associated references in the already included literature were also detected.
3. WalKR Two-Component Signal Transduction System and Resistance of Enterococcus Faecalis
3.1. Regulation of E. faecalis on Biofilm Formation
E. faecalis is characterized by its ability to survive in a high-sodium-chloride concertation and tolerate both acid and alkaline conditions. With the widespread use of antibiotics, E. faecalis as a pathogenic bacterium has gradually emerged with antibiotic resistance. Those adaptive capabilities are closely related to the E. faecalis biofilm formation.
Biofilm is mainly developed by packed microcolonies and extracellular polymeric substances (EPSs). Multiple genes have been identified to play an important role in biofilm biogenesis. Genes encode proteinaceous adhesins such as LPxTG surface proteins, autolysins, and glycolipids, contributing to intercellular adhesion in biofilm formation. EF3314 is a putative surface-exposed antigenic protein in E. faecalis. It is considered as an adhesin for biofilm formation.
Polysaccharides, as well as autolysins and proteases, are thought to contribute to EPS production, and therefore affect biofilm maturation. Gene cluster epa (enterococcal polysaccharide antigen) is involved in the biosynthesis of cell-wall-associated polysaccharides. In E. faecalis, the epa gene cluster encodes enzymes and transporters involving synthesis of nucleotide sugar precursors in the cytoplasm, formation and polymerization of repeating units, and export to the cell surface, which contribute to biofilm formation, resistance to enterococcal polysaccharide antigen (PMN) killing, and virulence [50].
eDNA is an important component of the extracellular matrix of bacterial biofilms, providing structural stability to the biofilm and protection against antimicrobials. Murein hydrolases, also referred to as autolysins, have been implicated in biofilm production [51]. In E. faecalis, autolysins such as AtlA, AtlB, and AtlC are involved in eDNA release. AtlA is identified as an N-acetylglucosaminidase [52]. The synergistical action with two additional peptidoglycan hydrolases AtlB and AtlC DNA regulates the release of eDNA [53]. The deletion of atlA not only delays the biofilm formation but also inhibits cells division and reduces the rate of cellular lysis [53].
Via proteolytic processing of the accumulation-associated protein, bacterial proteases contribute to biofilm formation [54,55]. Two proteases produced by E. faecalis such as GelE and SprE have been shown to regulate bacterial autolysis as well as eDNA release and, thus, contribute to E. faecalis biofilm formation, playing important roles in the pathogenesis of various diseases, including endophthalmitis, peritonitis, endocarditis, and orthopedic implant infections [56]. Regarding orthopedic implant infections, E. faecalis with high gelatinase production is a prevalent isolate [57]. The quorum-sensing Fsr two-component system is comprised of three genes involving fsrA, fsrB, and fsrC. By sensing the extracellular accumulation of a peptide lactone encoded at the C terminus of the FsrB protein, the FsrC histidine kinase is activated, subsequently irrigating response regulator FsrA. Inactivation of the fsr-controlled gene gelE inhibits the biofilm formation [31].
In enterococcal surface proteins (Esps), LPxTG-type surface proteins can covalently immobilize the surface protein to the cell-wall peptidoglycan, involved in cell-to-cell adhesion and biofilm formation [58]. LPxTG-type surface proteins may be partially mediated by the N-terminal moiety of the protein and interacts with additional E. faecalis-specific factors to enhance the biofilm formation [58,59].
Lipoteichoic acid (LTA) and polysaccharide are also involved in biofilm formation via interactions with environmental molecules. In E. faecalis, the dltABCD operon is required to obtain D-alanylation of LTA, which is an essential constituent of the Gram-positive bacterial cell wall [60]. The deletion of the dltA gene induces the absence of D-alanine in the LTA and a stronger negative net charge on the bacterial cell surface. D-alanine esters as positively charged groups can modulate negatively charged teichoic acids. Subsequently, the biofilm formation was significantly decreased in E. faecalis with reduced adherence to epithelial cells, while the susceptibility to cationic antimicrobial peptides was increased [61,62].
Enterococcal binding substance (EBS), a kind of cognate receptor for the aggregation substance, such as cell wall LTA, is necessary for mating complexes in biofilm formation [59,63]. Aggregation substances (ASs), such as Asa1, Asp1, and Acs10, promote the conjugation by directing bacterial aggregation, enables cell–cell contact between donor and recipient strains, and increases the E. faecalis virulence [64,65]. In a dose-dependent manner, Asc10 with an LTA aggregation domain is located near the N-terminal of E. Faecalis LTA [66]. The AS protein is comprised of an N-terminal domain (output signal), a variable region, a central domain (responsible for aggregation), and two Arg-Gly-Asp (RGD) motifs (implicate in binding host cell integrins) [66,67,68]. The expression of the AS protein can be induced by the peptide pheromone, which is secreted from plasmid-free recipient cells, or can be induced by host factors that may act by shifting the effective ratios of endogenous cCF10/iCF10 [65,69,70,71,72,73,74].
The E. faecalis WalRK system regulates the various metabolisms including cell wall construction, osmotic protection, biofilm formation, and drug resistance, which are significantly related to bacterial pathogenicity [39]. Furthermore, the drug resistance in E. faecalis infection is worrisome, and even some Enterococcus spp. are completely resistant to all antimicrobial drug regimens [12,75]. The regulation of E. faecalis by the WalRK system includes the physiological metabolisms, biofilm and cell wall formation, drug resistance, and immunity reaction with the host. Considering the WalRK regulations above, it as a novel target can be developed and available for infection disease, especially for the multidrug-resistant vancomycin-resistant Enterococci (VRE).
Histidine kinase WalK is a transmembrane protein that senses external signals and possesses kinase, phosphotransferase, and phosphatase activities, while the response regulator WalR contains a functional domain (REC) that accepts a phosphate group for autophosphorylation. The kinase ATP-binding domain (HATPase_c) of WalK is stimulated and activated by extracellular signals and then causes phosphorylation at the histidine site of WalK (HisKA domain). The phosphoryl group is first transmitted from the phosphorylated WalK and then to the aspartic acid residue of WalR, leading to conformational change and exposure of the DNA-binding site. Phosphorylated WalR then binds the DNA promoter motif and is involved in transcriptional regulation of bacteria metabolism [48]. In our previous study [76], an antisense walR negatively regulates the walR expression, leading to the biofilm formation reduction and extracellular polysaccharide synthesis, significantly decreasing the pathogenicity of E. faecalis. The roles of WalRK in biofilm formation attracts increasing interest on a potential target of antibacterial and antibiofilm [77]. However, the mechanism of WalRK modulating biofilm formation remains largely unrevealed [78].
3.2. Antibiotic Resistance of Enterococcus faecalis
Antibiotic-resistant E. faecalis is of concern and contributes to difficult-to-treat nosocomial infections [79]. The main reasons for multidrug-resistant enterococci emergence include intrinsic resistance to antimicrobial agents such as beta lactams and aminoglycosides, and mobile elements acquired resistance against glycopeptides, quinolones, tetracyclines, and streptogramin [80]. The acquired vanA and vanB genotypes are the most common glycopeptide resistance in E. faecalis and are regulated by the VanRS and VanRBSB TCSs [81]. The vancomycin resistance operon modifies the vancomycin-binding target by synthesis of peptidoglycan precursors that terminate in D-lactate or D-serine. Instead of normal D-alanine sidechain terminus, the modified vancomycin resistance operon significantly decreases the affinity vancomycin on E. faecalis [82]. With the evolution of resistance, the last-resort antibiotics, such as daptomycin and linezolid, for multidrug-resistant Enterococcal infections are limited [79].
E. faecalis produces a specific penicillin-binding protein (PBP5) that mediates high-level intrinsic resistance to the cephalosporin class of β-lactam antibiotics. Comenge et al. first described that the regulatory CroRS TCS is essential for PBP5-mediated β-lactam resistance [17]. In further dissection of the CroRS TCS, a noncognate histidine kinase CisS is capable of influencing CroR to mediate resistance to cell wall stresses such as cephalosporins and glycopeptides. The cross-talk of CroRS and CisRS responds to the vancomycin [83]. Vancomycin is the only identified stimuli for CisRS thus far and CisRS can also interact with VanRS for resistance [84].
Daptomycin (DAP) is a lipopeptide antibiotic with potent in vitro bactericidal activity against VRE [85]. By binding with calcium, DAP can form a cationic moiety and disrupts membranes to play its potential antimicrobial role [86]. However, reports of DAP-insensitive enterococci strains have become increasingly common [86]. Tran et al. identified the resistance of Enterococcus faecium (E. Faecium) to daptomycin associated with YycFG system mutation. In addition, this resistance mechanism was also related with the LiaFSR system in E. faecium [49]. The LiaFSR three-component system controls the cell envelope stress response of E. Faecalis and its mutation results in the resistance of daptomycin [87]. E. Faecalis and E. Faecium both belong to Enterococcus, and they share a great similarity in gene composition. From this point, it may be inferred that the YycFG system of E. Faecalis also plays a role in DAP resistance.
The two-component systems in bacteria can cross-talk with each other to regulate a variety of cellular processes, including biofilm formation, virulence expression, and drug resistance [26]. For Gram-positive bacteria, the relationship between the WalRK TCS and other TCSs such as VanSB, CovRS, and SaeSR has been explored. In Streptococcus mutans (S. mutans), VicR and CovR can both regulate a group of genes of extracellular polysaccharides synthesis. However, VicR positively regulates these genes in most cases, while CovR modulates inversely [88]. For S. aureus, the VicRK TCS can activate the SaeSR TCS to regulate virulence factors [89]. In E. faecalis, VanSB can phosphorylate VicR from S. pneumoniae and raise a species cross-talking [6,26]. However, there is rare evidence suggesting interaction between WalRK and other TCSs such as VanSR in E. faecalis.
3.3. Regulatory Roles of the WalRK TCS in Response to Host Immunity
TCSs in pathogenic bacteria can also adjust responsible immunity activities and infect microenvironments in hosts. For S. aureus, WalRK positively regulates virulence genes through a virulence factor regulation system SaeSR TCS, promoting the polymorphonuclear leukocytes (PMNs) lysis and playing an essential role in innate immunity evasion [90]. Additionally, adaptive immunity can enhance the effect of innate immune cells and influence host susceptibility to microorganism invaders [91]. By modulating the virulence expression, the evasion mechanisms from the adaptive immune system are developed [89,92]. In S. aureus, a second immunoglobulin binding protein (Sbi) is secreted as a virulence factor, binding with the Fc portion of IgG, and interferes with host adaptive immune responses. In a previous study, WalRK positively regulated biofilms aggregation and virulence genes expression, controlling the progress of the infection condition in the host [93]. However, the specific mechanism of the WalRK TCS on modulating the interaction of the host and E. faecalis needs to be further explored.
4. Chemical Compounds Act on WalRK to Inhibit the Pathogenicity of Bacteria
Due to the important role of WalRK in Gram-positive bacteria such as E. faecalis, S. aureus, S. epidermidis, and S. mutans [94,95,96,97], many attempts were applied on WalRK to inhibit pathogenicity [94].
Clinically, iodoform is widely used as a disinfectant. It has a strong effect on aerobic Gram-positive bacteria and can enhance antibacterial activity against E. faecalis when combined with calcium hydroxide [98]. Therefore, it is used in dental treatment, and can be used for the treatment of periapical periodontitis when in combination with calcium hydroxide [99]. However, because of its tendency to cause allergic reactions and cytotoxicity to epithelial cells and macrophages, new drugs need to be developed [100].
4.1. Antibiotics-Based Agents on WalRK
Many studies are committed to looking for antibacterial substances from microorganism, such as actinomycin, a good natural antibiotic derived from Actinomycetes.
The autophosphorylation of WalK is an essential step for bacterial pathogenicity. An actinomycin metabolite, waldiomycin, belongs to the family of anguclin antibiotics, which is similar to dioxin in structure, and it can affect the expression of related genes on cell wall metabolism, cell proliferation, and aggregation. Specifically, this inhibitor was found to play a role in inhibiting the function of WalK phosphorylation, attributed to the antibacterial effects mentioned above [94,96]. Subsequently, this waldiomycin has an antibacterial activity against Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA) and B. subtilis. Okada et al. pointed out that by binding to the WalK cytoplasmic domain, walkmycin B, which was the main product of Streptomyces sp. (MK632-100F11), inhibited WalK phosphorylation [101]. The H-box region is an essential motif of WalK, and Kato et al. found that waldiomycin interfered with various cellular processes of B. subtilis by targeting the H-box region of WalK and other HK [102].
Zerumbone1 is a kind of monocyclic sesquiterpene whose derivatives have high biological activities, including its ring opening derivative 2 (Figure 1). Kitayama et al. pointed out that Zerumbone ring opening derivative 2 can inhibit the autophosphorylation of WalK in B. subtilis, while it cannot inhibit drug-resistant bacteria, such as MRSA and VRE [103].
At the same time, signermycin B was found in a temperature-sensitive B. subtilis walR mutant (CNM2000) [104]. The signermycin B can inhibit self-phosphorylation by targeting the conserved dimer domain of WalK and inhibit the activity of WalR to hinder the function of the walKR system, achieving an antibacterial effect.
As the existence of E. faecalis biofilm has greatly improved the resistance of E. faecalis to existing antibiotic therapy, Lin et al. investigated the effect of derivatives from a kind of probiotic named B. subtilis natto on the E. faecalis biofilm formation [105]. Natto treatment showed downregulation of the E. faecalis walRK system transcription, which resulted in peptidoglycan and glycolipid biosynthesis inhibition and a reduction in extracellular polysaccharide synthesis. These studies showed that B. subtilis natto may help to control the biofilm of E. faecalis, and then affect the drug resistance of E. faecalis.
4.2. Novel Screened Antibacterial Substances on WalRK
Recently, many novel antibacterial substances have been developed via high-throughput screening systems with a high efficiency.
Qin et al. verified a series of novel inhibitors on the S. epidermidis WalK protein by using structure-based virtual screening (SBVs) in a small-molecule lead compound library [106]. There, seven inhibitors belonging to four different chemical structures were identified: three thiazolidinone analogs (compounds 2, 5, and 7), two benzamide analogs (compounds 1 and 3), a furan derivative (compound 4), and a pyrimidine ketone derivative (compound 6). By replacing different functional groups in Compound 2 (C27H28O5N2S) (Figure 2), a series of derivatives were designed, such as H2-38, H2-39, H2-74, and H2-81 (Table 1) [107]. Those derivatives as new antibacterial agents targeting WalK can effectively eradicate against clinical Staphylococcus isolates such as multidrug-resistant Staphylococcus spp. and S. aureus. H2-60 (C27H16F2O2N3S2) and H2-81(C27H17FO2N3S2) are two thiazolidinone derivatives. Both derivatives are proved to have an effect on WalK. Biofilm has greatly improved the resistance of E. faecalis to existing antibiotic therapy. In E. faecalis, Chen et al. identified two derivatives that play a role against biofilm production by repression of WalK kinase phosphorylation activity [108]. When combined with traditional antibiotics such as daptomycin, H2-60 can even synergistically enhance the sensitivity of E. faecalis than single application.
In other species, such as Streptococcus agalactiae, the verified H2-60 and H2-81 can significantly inhibit biofilm formation and bacterial growth [109]. Furuta et al. screened and identified a compound I-8-15 (1-dodecyl-2-isopropyl imidazole), which can specifically inhibit the WalK of S. aureus, resulting in conformational changes and inhibiting dimerization of WalK [110]. By this mechanism, I-8-15 showed a significant antibacterial activity against MRSA and VRE.
In addition, Gotoh et al. also identified wallycin A (4-methoxy-1-naphthol) and wallycin B (1,6-dimethyl-3-[4-(trifluoromethyl) phenyl] pyrimido [5,4-e][1,2,4]triazine-5, 7-dione) compounds through the high-throughput screening system [95]. IclR is a regulatory protein containing the N-terminal DNA binding domain of the wing helix trans helix motif and the C-terminal regulatory domain of the protein, and the binding of signal molecules to the C-terminal domain of IclR is considered to inhibit the transcription of target genes by regulating DNA binding activity or the polymerization of IclR. By analysis, it was proved that these two compounds can inhibit the phosphate transfer from P-WalKtru to WalR. As a result, they can inactivate the IclR-WalR chimeric repressor, as walR inhibitors.
4.3. Nucleic-Acid-Based Interfering walRK for Treatment
Antisense RNA (asRNA) is a single-stranded RNA reverse complement to the targeted mRNA. It can inhibit the translation or transcription of target mRNA by recruiting the RNase to degrade RNA duplex structures. Using this property, RNA interference technology is developed to inhibit the transcription of target genes to affect physiological functions [111].
E. faecalis is the main pathogen of persistent periapical periodontitis. The E. faecalis biofilm formation is related to the WalRK modulation. How to inhibit WalRK expression and reduce biofilm formation attracts a prospective research topic. Our previous study identified an endogenous antisense walR (ASwalR) inhibiting walR expression [112]. With ASwalR interference, the biofilm formation of E. faecalis is significantly reduced and sensitivity to traditional chlorhexidine is increased. To further improve the efficiency of ASwalR, a graphene-oxide (GO)–polyethyleneimine (PEI)-based transformation strategy is applied, indicating that it can be used as a potential supplementary therapy for infection treatment [113].
4.4. Bacteriophage Therapy
Phage is the general name of viruses that infect microorganisms such as bacteria, fungi, algae, actinomycetes, and spirochetes. The size of phages is generally small, with an incomplete cell structure, and only contains a single nucleic acid. In addition, some of the phages can cause the lysis of host bacteria. By nucleic acid invasion and replication, the phages can kill bacteria as a novel treatment mode. Unlike traditional antibiotics, phages replicate themselves in the bacteria, and this repeating process effectively amplifies its antibacterial efficiencies. Because of antibiotic resistance and the fact that antibiotics may destroy the microbial balance in the body, phage therapy is less likely to develop resistance and is also highly microbial-specific [114].
However, phage therapy has some corresponding disadvantages including the specificity to target bacteria, easily producing corresponding tolerance under selection, being contaminated by bacteria used for culture, and rapidly being removed from the body and other unclear efficacies [115]. Therefore, many studies have been performed to improve the above shortcomings.
To overcome short duration, Merril et al. screened a mutation of the main phage head protein E in capsid proteins of phage K and phage P22, in which a long-half-life phage was acquired [116]. Meanwhile, chemical modification with polyethylene glycol (PEG) can significantly improve the cycle half-life of phages by reducing the release level of helper-T-cell-type-Ⅰ-related cytokines (IFN-γ and IL-6) [117].
The biofilm formation significantly decreases the sensitivity of bacteria on phages. To strengthen the effect of phages, Lu modified a phage to encode enzymes [118]. Enzymes can hydrolyze extracellular polymeric substances and help the phage to bind to the receptor. Antibiotic efflux pumps are the essential resistance mechanisms. The combination of antibiotic treatment and bacteriophages acting on the expression of antibiotic efflux pumps can make bacteria more sensitive to antibiotics [119,120].
In E. faecalis, phages can potentially be a genetic scheme for treatment. Duerkop et al. found sewage phages in urban sewage [121]. Through phage infection proteins for Enterococcus faecalis (PIPEF), sewage phages inhibit the colonization of E. faecalis in the intestine, playing a therapeutic role.
Therefore, the phage therapy is also expected as a good scheme for the infection treatment. We proposed a hypothetical treatment, which integrates the antisense fragment of the walRK gene or inhibitor encoding the WalRK protein on the phage genome specific to E. faecalis and modified by PEG, and then injects it into the human body to treat E. faecalis infection to inhibit the biofilm formation, cooperating with corresponding antibiotic treatment.
5. Conclusions
Biofilm formation in E. faecalis induces a high adaption to the environment and causes severe infections. Many factors including polysaccharides as well as autolysis, proteases, and eDNA regulate biofilm formation. These factors are regulated by several important regulatory systems involving the TCSs. The highly conserved WalRK, one of 17 TCSs, is the only essential TCS in E. faecalis. In addition, various metabolisms, including cell wall construction, drug resistance, and interactions between regulatory systems and resistance to the host immune system, can be regulated by the WalRK system. Therefore, WalRK has been identified as a key target for the infection control. At present, novel antibiotics, screened antibacterial substances, and nucleic-acid-based agents interfering on WalRK phosphorylation or expression have been investigated for infection treatment. Meanwhile, promising phage therapy, a potentially genetic scheme, shows a good inhibition on bacterial growth. Therefore, suppressing the action of WalRK on bacterial infection with programed phages such as antisense fragment integration will be a topic of great interest.
Conceptualization, Formal Analysis, S.W. and Q.P.; Data Collection, J.Z. and R.F.; Writing—Original Draft Preparation, J.Z. and R.F.; Writing—Review and Editing, S.W., Q.P. and L.L. All authors have read and agreed to the published version of the manuscript.
Not applicable.
Not applicable.
Not applicable.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Chemical composition of Thiazolidinone Analogs Compound 2 Derivatives.
Thiazolidinone Analogues Compound 2 Derivatives | |
---|---|
Name | Chemical Formula |
H2-38 | 3-{5-{{3-(4-chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-5-ylidene}methyl}furan-2-yl}benzoic acid |
H2-39 | 4-{5-{{3-(4-chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-5-ylidene}methyl}furan-2-yl}benzoic acid |
H2-74 | 2-{4-{{3-(4-chlorophenyl)-2-[(4-chlorophenyl)imino]-4-oxothiazolidin-5-ylidene}methyl}phenoxy}acetic acid |
H2-81 | 4-{5-{{3-(4-fluorophenyl)-2-[(4-phenyl)imino]-4-oxothiazolidin-5-ylidene}methyl}thiophene-2-yl} benzoic acid |
References
1. Facklam, R. What happened to the streptococci: Overview of taxonomic and nomenclature changes. Clin. Microbiol. Rev.; 2002; 15, pp. 613-630. [DOI: https://dx.doi.org/10.1128/CMR.15.4.613-630.2002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12364372]
2. Rams, T.E.; Feik, D.; Young, V.; Hammond, B.F.; Slots, J. Enterococci in human periodontitis. Oral Microbiol. Immunol.; 1992; 7, pp. 249-252. [DOI: https://dx.doi.org/10.1111/j.1399-302X.1992.tb00034.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1408361]
3. Distel, J.W.; Hatton, J.F.; Gillespie, M.J. Biofilm formation in medicated root canals. J. Endod.; 2002; 28, pp. 689-693. [DOI: https://dx.doi.org/10.1097/00004770-200210000-00003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12398165]
4. Mohamed, J.A.; Huang, D.B. Biofilm formation by enterococci. J. Med. Microbiol.; 2007; 56, Pt 2, pp. 1581-1588. [DOI: https://dx.doi.org/10.1099/jmm.0.47331-0]
5. Figdor, D.; Davies, J.K.; Sundqvist, G. Starvation survival, growth and recovery of Enterococcus faecalis in human serum. Oral Microbiol. Immunol.; 2003; 18, pp. 234-239. [DOI: https://dx.doi.org/10.1034/j.1399-302X.2003.00072.x]
6. McHugh, C.P.; Zhang, P.; Michalek, S.; Eleazer, P.D. pH required to kill Enterococcus faecalis in vitro. J. Endod.; 2004; 30, pp. 218-219. [DOI: https://dx.doi.org/10.1097/00004770-200404000-00008] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15085049]
7. Sedgley, C.M.; Lennan, S.L.; Appelbe, O.K. Survival of Enterococcus faecalis in root canals ex vivo. Int. Endod. J.; 2005; 38, pp. 735-742. [DOI: https://dx.doi.org/10.1111/j.1365-2591.2005.01009.x]
8. Stevens, R.H.; Grossman, L.I. Evaluation of the antimicrobial potential of calcium hydroxide as an intracanal medicament. J. Endod.; 1983; 9, pp. 372-374. [DOI: https://dx.doi.org/10.1016/S0099-2399(83)80187-3]
9. Gilmore, M.S.; Ferretti, J.J. Microbiology. The thin line between gut commensal and pathogen. Science; 2003; 299, pp. 1999-2002. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12663906][DOI: https://dx.doi.org/10.1126/science.1083534]
10. Hunt, C.P. The emergence of enterococci as a cause of nosocomial infection. Br. J. Biomed. Sci.; 1998; 55, pp. 149-156.
11. Jett, B.D.; Huycke, M.M.; Gilmore, M.S. Virulence of enterococci. Clin. Microbiol. Rev.; 1994; 7, pp. 462-478. [DOI: https://dx.doi.org/10.1128/CMR.7.4.462] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/7834601]
12. Moellering, R.C., Jr. Emergence of Enterococcus as a significant pathogen. Clin. infect. Dis.; 1992; 14, pp. 1173-1176. [DOI: https://dx.doi.org/10.1093/clinids/14.6.1173] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1623072]
13. Woodford, N. Glycopeptide-resistant enterococci: A decade of experience. J. Med. Microbiol.; 1998; 47, pp. 849-862. [DOI: https://dx.doi.org/10.1099/00222615-47-10-849]
14. Ali, L.; Goraya, M.U.; Arafat, Y.; Ajmal, M.; Chen, J.L.; Yu, D. Molecular Mechanism of Quorum-Sensing in Enterococcus faecalis: Its Role in Virulence and Therapeutic Approaches. Int. J. Mol. Sci.; 2017; 18, 960. [DOI: https://dx.doi.org/10.3390/ijms18050960]
15. Marino, A.; Munafò, A.; Zagami, A.; Ceccarelli, M.; Di Mauro, R.; Cantarella, G.; Bernardini, R.; Nunnari, G.; Cacopardo, B. Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis Endocarditis: A Literature Review. J. Clin. Med.; 2021; 10, 4594. [DOI: https://dx.doi.org/10.3390/jcm10194594] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34640612]
16. Romay, E.; Pericàs, J.M.; García-País, M.J.; Hernández-Meneses, M.; Ayuso, B.; García-González, J.; Garcés-Durán, R.V.; Rabuñal, R.; Alonso-García, P.; García-Garrote, F. et al. On Behalf Of Lucus Augusti And Hospital Clinic Endocarditis Teams. Relationship among Streptococcus gallolyticus Subsp. gallolyticus, Enterococcus faecalis and Colorectal Neoplasms in Recurrent Endocarditis: A Historical Case Series. J. Clin. Med.; 2022; 11, 2181. [DOI: https://dx.doi.org/10.3390/jcm11082181] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35456274]
17. Comenge, Y.; Quintiliani, R., Jr.; Li, L.; Dubost, L.; Brouard, J.P.; Hugonnet, J.E.; Arthur, M. The CroRS two-component regulatory system is required for intrinsic beta-lactam resistance in Enterococcus faecalis. J. Bacteriol.; 2003; 185, pp. 7184-7192. [DOI: https://dx.doi.org/10.1128/JB.185.24.7184-7192.2003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14645279]
18. Frère, J.M.; Joris, B. Penicillin-sensitive enzymes in peptidoglycan biosynthesis. Crit. Rev. Microbiol.; 1985; 11, pp. 299-396. [DOI: https://dx.doi.org/10.3109/10408418409105906]
19. Tinoco, J.M.; Buttaro, B.; Zhang, H.; Liss, N.; Sassone, L.; Stevens, R. Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms. Arch. Oral Biol.; 2016; 71, pp. 80-86. [DOI: https://dx.doi.org/10.1016/j.archoralbio.2016.07.001]
20. Lindenstrauss, A.G.; Behr, J.; Ehrmann, M.A.; Haller, D.; Vogel, R.F. Identification of fitness determinants in Enterococcus faecalis by differential proteomics. Arch. Microbiol.; 2013; 195, pp. 121-130. [DOI: https://dx.doi.org/10.1007/s00203-012-0857-3]
21. Centeno, J.A.; Menendez, S.; Hermida, M.; Rodríguez-Otero, J.L. Effects of the addition of Enterococcus faecalis in Cebreiro cheese manufacture. Int. J. Food Microbiol.; 1999; 48, pp. 97-111. [DOI: https://dx.doi.org/10.1016/S0168-1605(99)00030-6] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10426446]
22. Nieto-Arribas, P.; Seseña, S.; Poveda, J.M.; Chicón, R.; Cabezas, L.; Palop, L. Enterococcus populations in artisanal Manchego cheese: Biodiversity, technological and safety aspects. Food Microbiol.; 2011; 28, pp. 891-899. [DOI: https://dx.doi.org/10.1016/j.fm.2010.12.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21569931]
23. Metaxopoulos, J.; Samelis, J.; Papadelli, M. Technological and Microbiological Evaluation of Traditional Processes as Modified for the Industrial Manufacturing of Dry Fermented Sausage in Greece. Ital. J. Food Sci.; 2001; 13, pp. 3-18.
24. Marchesini, B.; Bruttin, A.; Romailler, N.; Moreton, R.S.; Stucchi, C.; Sozzi, T. Microbiological events during commercial meat fermentations. J. Appl. Bacteriol.; 1992; 73, pp. 203-209. [DOI: https://dx.doi.org/10.1111/j.1365-2672.1992.tb02979.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1399914]
25. Wunderlich, P.F.; Braun, L.; Fumagalli, I.; D’Apuzzo, V.; Heim, F.; Karly, M.; Lodi, R.; Politta, G.; Vonbank, F.; Zeltner, L. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. J. Int. Med. Res.; 1989; 17, pp. 333-338. [DOI: https://dx.doi.org/10.1177/030006058901700405]
26. Hancock, L.E.; Perego, M. Systematic inactivation and phenotypic characterization of two-component signal transduction systems of Enterococcus faecalis V583. J. Bacteriol.; 2004; 186, pp. 7951-7958. [DOI: https://dx.doi.org/10.1128/JB.186.23.7951-7958.2004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15547267]
27. Ma, P.; Yuille, H.M.; Blessie, V.; Göhring, N.; Iglói, Z.; Nishiguchi, K.; Nakayama, J.; Henderson, P.J.; Phillips-Jones, M.K. Expression, purification and activities of the entire family of intact membrane sensor kinases from Enterococcus faecalis. Mol. Membr. Biol.; 2008; 25, pp. 449-473. [DOI: https://dx.doi.org/10.1080/09687680802359885] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18785057]
28. Laguri, C.; Phillips-Jones, M.K.; Williamson, M.P. Solution structure and DNA binding of the effector domain from the global regulator PrrA (RegA) from Rhodobacter sphaeroides: Insights into DNA binding specificity. Nucleic Acids Res.; 2003; 31, pp. 6778-6787. [DOI: https://dx.doi.org/10.1093/nar/gkg891]
29. Hoch, J.A.; Silhavy, T.J. Two-Component Signal Transduction; ASM Press: Washington, DC, USA, 1995; Volume xvi, 488.
30. Tierney, A.R.; Rather, P.N. Roles of two-component regulatory systems in antibiotic resistance. Future Microbiol.; 2019; 14, pp. 533-552. [DOI: https://dx.doi.org/10.2217/fmb-2019-0002]
31. Hancock, L.E.; Perego, M. The Enterococcus faecalis fsr two-component system controls biofilm development through production of gelatinase. J. Bacteriol.; 2004; 186, pp. 5629-5639. [DOI: https://dx.doi.org/10.1128/JB.186.17.5629-5639.2004]
32. Qin, X.; Singh, K.V.; Weinstock, G.M.; Murray, B.E. Effects of Enterococcus faecalis fsr genes on production of gelatinase and a serine protease and virulence. infect. Immun.; 2000; 68, pp. 2579-2586. [DOI: https://dx.doi.org/10.1128/IAI.68.5.2579-2586.2000] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10768947]
33. Sifri, C.D.; Mylonakis, E.; Singh, K.V.; Qin, X.; Garsin, D.A.; Murray, B.E.; Ausubel, F.M.; Calderwood, S.B. Virulence effect of Enterococcus faecalis protease genes and the quorum-sensing locus fsr in Caenorhabditis elegans and mice. infect. Immun.; 2002; 70, pp. 5647-5650. [DOI: https://dx.doi.org/10.1128/IAI.70.10.5647-5650.2002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12228293]
34. Goh, H.M.S.; Yong, M.H.A.; Chong, K.K.L.; Kline, K.A. Model systems for the study of Enterococcal colonization and infection. Virulence; 2017; 8, pp. 1525-1562. [DOI: https://dx.doi.org/10.1080/21505594.2017.1279766] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28102784]
35. Thurlow, L.R.; Thomas, V.C.; Narayanan, S.; Olson, S.; Fleming, S.D.; Hancock, L.E. Gelatinase contributes to the pathogenesis of endocarditis caused by Enterococcus faecalis. infect. Immun.; 2010; 78, pp. 4936-4943. [DOI: https://dx.doi.org/10.1128/IAI.01118-09] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20713628]
36. Park, S.Y.; Kim, K.M.; Lee, J.H.; Seo, S.J.; Lee, I.H. Extracellular gelatinase of Enterococcus faecalis destroys a defense system in insect hemolymph and human serum. infect. Immun.; 2007; 75, pp. 1861-1869. [DOI: https://dx.doi.org/10.1128/IAI.01473-06] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17261598]
37. Evers, S.; Courvalin, P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J. Bacteriol.; 1996; 178, pp. 1302-1309. [DOI: https://dx.doi.org/10.1128/jb.178.5.1302-1309.1996]
38. Hancock, L.; Perego, M. Two-component signal transduction in Enterococcus faecalis. J. Bacteriol.; 2002; 184, pp. 5819-5825. [DOI: https://dx.doi.org/10.1128/JB.184.21.5819-5825.2002]
39. Kuroda, M.; Kuwahara-Arai, K.; Hiramatsu, K. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem. Biophys. Res. Commun.; 2000; 269, pp. 485-490. [DOI: https://dx.doi.org/10.1006/bbrc.2000.2277]
40. West, A.H.; Stock, A.M. Histidine kinases and response regulator proteins in two-component signaling systems. Trends Biochem. Sci.; 2001; 26, pp. 369-376. [DOI: https://dx.doi.org/10.1016/S0968-0004(01)01852-7]
41. Fabret, C.; Hoch, J.A. A two-component signal transduction system essential for growth of Bacillus subtilis: Implications for anti-infective therapy. J. Bacteriol.; 1998; 180, pp. 6375-6383. [DOI: https://dx.doi.org/10.1128/JB.180.23.6375-6383.1998]
42. Inouye, M.; Dutta, R. Histidine Kinases in Signal Transduction; Academic Press: Amsterdam, The Netherlands, Boston, MA, USA, 2003; Volume xviii, 520p. [DOI: https://dx.doi.org/10.1016/B978-0-12-372484-7.X5000-0]
43. Mascher, T.; Helmann, J.D.; Unden, G. Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol. Mol. Biol. Rev.; 2006; 70, pp. 910-938. [DOI: https://dx.doi.org/10.1128/MMBR.00020-06] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17158704]
44. Winkler, M.E.; Hoch, J.A. Essentiality, bypass, and targeting of the YycFG (VicRK) two-component regulatory system in gram-positive bacteria. J. Bacteriol.; 2008; 190, pp. 2645-2648. [DOI: https://dx.doi.org/10.1128/JB.01682-07]
45. Gao, R.; Mack, T.R.; Stock, A.M. Bacterial response regulators: Versatile regulatory strategies from common domains. Trends Biochem. Sci.; 2007; 32, pp. 225-234. [DOI: https://dx.doi.org/10.1016/j.tibs.2007.03.002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17433693]
46. Stock, A.M.; Robinson, V.L.; Goudreau, P.N. Two-component signal transduction. Annu. Rev Biochem.; 2000; 69, pp. 183-215. [DOI: https://dx.doi.org/10.1146/annurev.biochem.69.1.183] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10966457]
47. Dubrac, S.; Bisicchia, P.; Devine, K.M.; Msadek, T. A matter of life and death: Cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol. Microbiol.; 2008; 70, pp. 1307-1322. [DOI: https://dx.doi.org/10.1111/j.1365-2958.2008.06483.x]
48. Tran, T.T.; Panesso, D.; Gao, H.; Roh, J.H.; Munita, J.M.; Reyes, J.; Diaz, L.; Lobos, E.A.; Shamoo, Y.; Mishra, N.N. et al. Whole-genome analysis of a daptomycin-susceptible enterococcus faecium strain and its daptomycin-resistant variant arising during therapy. Antimicrob. Agents Chemother.; 2013; 57, pp. 261-268. [DOI: https://dx.doi.org/10.1128/AAC.01454-12]
49. Wagner, C.; Saizieu, A.d.; Schönfeld, H.J.; Kamber, M.; Lange, R.; Thompson, C.J.; Page, M.G. Genetic analysis and functional characterization of the Streptococcus pneumoniae vic operon. infect. Immun.; 2002; 70, pp. 6121-6128. [DOI: https://dx.doi.org/10.1128/IAI.70.11.6121-6128.2002]
50. Teng, F.; Singh, K.V.; Bourgogne, A.; Zeng, J.; Murray, B.E. Further characterization of the epa gene cluster and Epa polysaccharides of Enterococcus faecalis. infect. Immun.; 2009; 77, pp. 3759-3767. [DOI: https://dx.doi.org/10.1128/IAI.00149-09]
51. Rice, K.C.; Mann, E.E.; Endres, J.L.; Weiss, E.C.; Cassat, J.E.; Smeltzer, M.S.; Bayles, K.W. The cidA murein hydrolase regulator contributes to DNA release and biofilm development in Staphylococcus aureus. Proc. Natl. Acad. Sci. USA; 2007; 104, pp. 8113-8118. [DOI: https://dx.doi.org/10.1073/pnas.0610226104]
52. Mesnage, S.; Chau, F.; Dubost, L.; Arthur, M. Role of N-acetylglucosaminidase and N-acetylmuramidase activities in Enterococcus faecalis peptidoglycan metabolism. J. Biol. Chem.; 2008; 283, pp. 19845-19853. [DOI: https://dx.doi.org/10.1074/jbc.M802323200]
53. Guiton, P.S.; Hung, C.S.; Kline, K.A.; Roth, R.; Kau, A.L.; Hayes, E.; Heuser, J.; Dodson, K.W.; Caparon, M.G.; Hultgren, S.J. Contribution of autolysin and Sortase a during Enterococcus faecalis DNA-dependent biofilm development. infect. Immun.; 2009; 77, pp. 3626-3638. [DOI: https://dx.doi.org/10.1128/IAI.00219-09] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19528211]
54. Rohde, H.; Burdelski, C.; Bartscht, K.; Hussain, M.; Buck, F.; Horstkotte, M.A.; Knobloch, J.K.; Heilmann, C.; Herrmann, M.; Mack, D. Induction of Staphylococcus epidermidis biofilm formation via proteolytic processing of the accumulation-associated protein by staphylococcal and host proteases. Mol. Microbiol.; 2005; 55, pp. 1883-1895. [DOI: https://dx.doi.org/10.1111/j.1365-2958.2005.04515.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15752207]
55. Martínez-García, S.; Rodríguez-Martínez, S.; Cancino-Diaz, M.E.; Cancino-Diaz, J.C. Extracellular proteases of Staphylococcus epidermidis: Roles as virulence factors and their participation in biofilm. APMIS; 2018; 126, pp. 177-185. [DOI: https://dx.doi.org/10.1111/apm.12805]
56. Nešuta, O.; Budešínský, M.; Hadravová, R.; Monincová, L.; Humpolicková, J.; Cerovský, V. How proteases from Enterococcus faecalis contribute to its resistance to short α-helical antimicrobial peptides. Pathog. Dis.; 2017; 29, 75. [DOI: https://dx.doi.org/10.1093/femspd/ftx091] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28830077]
57. Arciola, C.R.; Baldassarri, L.; Campoccia, D.; Creti, R.; Pirini, V.; Huebner, J.; Montanaro, L. Strong biofilm production, antibiotic multi-resistance and high gelE expression in epidemic clones of Enterococcus faecalis from orthopaedic implant infections. Biomaterials; 2008; 29, pp. 580-586. [DOI: https://dx.doi.org/10.1016/j.biomaterials.2007.10.008] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18029010]
58. Paganelli, F.L.; Willems, R.J.; Leavis, H.L. Optimizing future treatment of enterococcal infections: Attacking the biofilm?. Trends Microbiol.; 2012; 20, pp. 40-49. [DOI: https://dx.doi.org/10.1016/j.tim.2011.11.001]
59. Shankar, N.; Lockatell, C.V.; Baghdayan, A.S.; Drachenberg, C.; Gilmore, M.S.; Johnson, D.E. Role of Enterococcus faecalis surface protein Esp in the pathogenesis of ascending urinary tract infection. infect. Immun.; 2001; 69, pp. 4366-4372. [DOI: https://dx.doi.org/10.1128/IAI.69.7.4366-4372.2001]
60. Coupri, D.; Budin-Verneuil, A.; Hartke, A.; Benachour, A.; Léger, L.; Lequeux, T.; Pfund, E.; Verneuil, N. Genetic and pharmacological inactivation of d-alanylation of teichoic acids sensitizes pathogenic enterococci to β-lactams. J. Antimicrob. Chemother.; 2019; 74, pp. 3162-3169. [DOI: https://dx.doi.org/10.1093/jac/dkz322]
61. Chuang-Smith, O.N.; Wells, C.L.; Henry-Stanley, M.J.; Dunny, G.M. Acceleration of Enterococcus faecalis biofilm formation by aggregation substance expression in an ex vivo model of cardiac valve colonization. PLoS ONE; 2010; 5, e15798. [DOI: https://dx.doi.org/10.1371/journal.pone.0015798]
62. Johnson, J.R.; Clabots, C.; Hirt, H.; Waters, C.; Dunny, G. Enterococcal aggregation substance and binding substance are not major contributors to urinary tract colonization by Enterococcus faecalis in a mouse model of ascending unobstructed urinary tract infection. infect. Immun.; 2004; 72, pp. 2445-2448. [DOI: https://dx.doi.org/10.1128/IAI.72.4.2445-2448.2004]
63. Dunny, G.M. Enterococcal sex pheromones: Signaling, social behavior, and evolution. Annu. Rev. Genet.; 2013; 47, pp. 457-482. [DOI: https://dx.doi.org/10.1146/annurev-genet-111212-133449]
64. Telford, J.L.; Barocchi, M.A.; Margarit, I.; Rappuoli, R.; Grandi, G. Pili in gram-positive pathogens. Nat. Rev. Microbiol.; 2006; 4, pp. 509-519. [DOI: https://dx.doi.org/10.1038/nrmicro1443] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16778837]
65. Olmsted, S.B.; Kao, S.M.; van Putte, L.J.; Gallo, J.C.; Dunny, G.M. Role of the pheromone-inducible surface protein Asc10 in mating aggregate formation and conjugal transfer of the Enterococcus faecalis plasmid pCF10. J. Bacteriol.; 1991; 173, pp. 7665-7672. [DOI: https://dx.doi.org/10.1128/jb.173.23.7665-7672.1991] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1938962]
66. Waters, C.M.; Hirt, H.; McCormick, J.K.; Schlievert, P.M.; Wells, C.L.; Dunny, G.M. An amino-terminal domain of Enterococcus faecalis aggregation substance is required for aggregation, bacterial internalization by epithelial cells and binding to lipoteichoic acid. Mol. Microbiol.; 2004; 52, pp. 1159-1171. [DOI: https://dx.doi.org/10.1111/j.1365-2958.2004.04045.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15130132]
67. Sava, I.G.; Heikens, E.; Huebner, J. Pathogenesis and immunity in enterococcal infections. Clin. Microbiol. Infect.; 2010; 16, pp. 533-540. [DOI: https://dx.doi.org/10.1111/j.1469-0691.2010.03213.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20569264]
68. Schmitt, A.; Jiang, K.; Camacho, M.I.; Jonna, V.R.; Hofer, A.; Westerlund, F.; Christie, P.J.; Berntsson, R.P. PrgB promotes aggregation, biofilm formation, and conjugation through DNA binding and compaction. Mol. Microbiol.; 2018; 109, pp. 291-305. [DOI: https://dx.doi.org/10.1111/mmi.13980]
69. Dunny, G.M.; Leonard, B.A.; Hedberg, P.J. Pheromone-inducible conjugation in Enterococcus faecalis: Interbacterial and host-parasite chemical communication. J. Bacteriol.; 1995; 177, pp. 871-876. [DOI: https://dx.doi.org/10.1128/jb.177.4.871-876.1995]
70. Leonard, B.A.; Podbielski, A.; Hedberg, P.J.; Dunny, G.M. Enterococcus faecalis pheromone binding protein, PrgZ, recruits a chromosomal oligopeptide permease system to import sex pheromone cCF10 for induction of conjugation. Proc. Natl. Acad. Sci. USA; 1996; 93, pp. 260-264. [DOI: https://dx.doi.org/10.1073/pnas.93.1.260]
71. Chandler, J.R.; Hirt, H.; Dunny, G.M. A paracrine peptide sex pheromone also acts as an autocrine signal to induce plasmid transfer and virulence factor expression in vivo. Proc. Natl. Acad. Sci. USA; 2005; 102, pp. 15617-15622. [DOI: https://dx.doi.org/10.1073/pnas.0505545102]
72. Hirt, H.; Schlievert, P.M.; Dunny, G.M. In vivo induction of virulence and antibiotic resistance transfer in Enterococcus faecalis mediated by the sex pheromone-sensing system of pCF10. infect. Immun.; 2002; 70, pp. 716-723. [DOI: https://dx.doi.org/10.1128/IAI.70.2.716-723.2002]
73. Galli, D.; Lottspeich, F.; Wirth, R. Sequence analysis of Enterococcus faecalis aggregation substance encoded by the sex pheromone plasmid pAD1. Mol. Microbiol.; 1990; 4, pp. 895-904. [DOI: https://dx.doi.org/10.1111/j.1365-2958.1990.tb00662.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/2120541]
74. Galli, D.; Friesenegger, A.; Wirth, R. Transcriptional control of sex-pheromone-inducible genes on plasmid pAD1 of Enterococcus faecalis and sequence analysis of a third structural gene for (pPD1-encoded) aggregation substance. Mol. Microbiol.; 1992; 6, pp. 1297-1308. [DOI: https://dx.doi.org/10.1111/j.1365-2958.1992.tb00851.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/1640831]
75. French, G.L. Enterococci and vancomycin resistance. Clin. Infect. Dis.; 1998; 27, (Suppl. 1), pp. S75-S83. [DOI: https://dx.doi.org/10.1086/514910] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9710674]
76. Wu, S.; Liu, Y.; Zhang, H.; Lei, L. The Susceptibility to Calcium Hydroxide Modulated by the Essential walR Gene Reveals the Role for Enterococcus faecalis Biofilm Aggregation. J. Endod.; 2019; 45, pp. 295-301.e2. [DOI: https://dx.doi.org/10.1016/j.joen.2018.11.011]
77. Chen, Z.; Song, K.; Shang, Y.; Xiong, Y.; Lyu, Z.; Chen, J.; Zheng, J.; Li, P.; Wu, Y.; Gu, C. et al. Selection and Identification of Novel Antibacterial Agents against Planktonic Growth and Biofilm Formation of Enterococcus faecalis. J. Med. Chem.; 2021; 64, pp. 15037-15052. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.1c00939]
78. Rice, L.B. Enterococcal Physiology and Antimicrobial Resistance: The Streetlight Just Got a Little Brighter. mBio; 2021; 12, pp. e03511-e03520. [DOI: https://dx.doi.org/10.1128/mBio.03511-20]
79. Van Harten, R.M.; Willems, R.J.L.; Martin, N.I.; Hendrickx, A.P.A. Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?. Trends Microbiol.; 2017; 25, pp. 467-479. [DOI: https://dx.doi.org/10.1016/j.tim.2017.01.004]
80. Jahansepas, A.; Aghazadeh, M.; Rezaee, M.A.; Hasani, A.; Sharifi, Y.; Aghazadeh, T.; Mardaneh, J. Occurrence of Enterococcus faecalis and Enterococcus faecium in Various Clinical Infections: Detection of Their Drug Resistance and Virulence Determinants. Microb. Drug Resist.; 2018; 24, pp. 76-82. [DOI: https://dx.doi.org/10.1089/mdr.2017.0049]
81. Arthur, M.; Quintiliani, R., Jr. Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob. Agents Chemother.; 2001; 45, pp. 375-381. [DOI: https://dx.doi.org/10.1128/AAC.45.2.375-381.2001]
82. Hegstad, K.; Mikalsen, T.; Coque, T.M.; Werner, G.; Sundsfjord, A. Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium. Clin. Microbiol. Infect.; 2010; 16, pp. 541-554. [DOI: https://dx.doi.org/10.1111/j.1469-0691.2010.03226.x]
83. Kellogg, S.L.; Kristich, C.J. Functional Dissection of the CroRS Two-Component System Required for Resistance to Cell Wall Stressors in Enterococcus faecalis. J. Bacteriol.; 2016; 198, pp. 1326-1336. [DOI: https://dx.doi.org/10.1128/JB.00995-15]
84. Depardieu, F.; Mejean, V.; Courvalin, P. Competition between VanU(G) repressor and VanR(G) activator leads to rheostatic control of vanG vancomycin resistance operon expression. PLoS Genet.; 2015; 11, e1005170. [DOI: https://dx.doi.org/10.1371/journal.pgen.1005170] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25898178]
85. Bloem, A.; Bax, H.I.; Yusuf, E.; Verkaik, N.J. New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis. J. Clin. Med.; 2021; 10, 1743. [DOI: https://dx.doi.org/10.3390/jcm10081743]
86. Smith, J.R.; Barber, K.E.; Raut, A.; Rybak, M.J. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. Antimicrob. Agents Chemother.; 2015; 59, pp. 2842-2848. [DOI: https://dx.doi.org/10.1128/AAC.00053-15] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25753639]
87. Arias, C.A.; Panesso, D.; McGrath, D.M.; Qin, X.; Mojica, M.F.; Miller, C.; Diaz, L.; Tran, T.T.; Rincon, S.; Barbu, E.M. et al. Genetic basis for in vivo daptomycin resistance in enterococci. N. Engl. J. Med.; 2011; 365, pp. 892-900. [DOI: https://dx.doi.org/10.1056/NEJMoa1011138] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21899450]
88. Stipp, R.N.; Boisvert, H.; Smith, D.J.; Höfling, J.F.; Duncan, M.J.; Mattos-Graner, R.O. CovR and VicRK regulate cell surface biogenesis genes required for biofilm formation in Streptococcus mutans. PLoS ONE; 2013; 8, e58271. [DOI: https://dx.doi.org/10.1371/journal.pone.0058271]
89. Wu, S.; Zhang, J.; Peng, Q.; Liu, Y.; Lei, L.; Zhang, H. The Role of Staphylococcus aureus YycFG in Gene Regulation, Biofilm Organization and Drug Resistance. Antibiotics; 2021; 10, 1555. [DOI: https://dx.doi.org/10.3390/antibiotics10121555]
90. Voyich, J.M.; Vuong, C.; DeWald, M.; Nygaard, T.K.; Kocianova, S.; Griffith, S.; Jones, J.; Iverson, C.; Sturdevant, D.E.; Braughton, K.R. et al. The SaeR/S gene regulatory system is essential for innate immune evasion by Staphylococcus aureus. J. Infect. Dis.; 2009; 199, pp. 1698-1706. [DOI: https://dx.doi.org/10.1086/598967]
91. Karauzum, H.; Datta, S.K. Adaptive Immunity gainst Staphylococcus aureus. Curr. Top Microbiol. Immunol.; 2017; 409, pp. 419-439. [DOI: https://dx.doi.org/10.1007/82_2016_1]
92. Qiu, Y.; Xu, D.; Xia, X.; Zhang, K.; Aadil, R.M.; Batool, Z.; Wang, J. Five major two components systems of Staphylococcus aureus for adaptation in diverse hostile environment. Microb. Pathog.; 2021; 159, 105119. [DOI: https://dx.doi.org/10.1016/j.micpath.2021.105119]
93. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Endogenous antisense walR RNA modulates biofilm organization and pathogenicity of Enterococcus faecalis. Exp. Ther. Med.; 2021; 21, 69. [DOI: https://dx.doi.org/10.3892/etm.2020.9501] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33365069]
94. Fakhruzzaman, M.; Inukai, Y.; Yanagida, Y.; Kino, H.; Igarashi, M.; Eguchi, Y.; Utsumi, R. Study on in vivo effects of bacterial histidine kinase inhibitor, Waldiomycin, in Bacillus subtilis and Staphylococcus aureus. J. Gen. Appl. Microbiol.; 2015; 61, pp. 177-184. [DOI: https://dx.doi.org/10.2323/jgam.61.177] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26582287]
95. Gotoh, Y.; Doi, A.; Furuta, E.; Dubrac, S.; Ishizaki, Y.; Okada, M.; Igarashi, M.; Misawa, N.; Yoshikawa, H.; Okajima, T. et al. Novel antibacterial compounds specifically targeting the essential WalR response regulator. J. Antibiot.; 2010; 63, pp. 127-134. [DOI: https://dx.doi.org/10.1038/ja.2010.4]
96. Igarashi, M.; Watanabe, T.; Hashida, T.; Umekita, M.; Hatano, M.; Yanagida, Y.; Kino, H.; Kimura, T.; Kinoshita, N.; Inoue, K. et al. Waldiomycin, a novel WalK-histidine kinase inhibitor from Streptomyces sp. MK844-mF10. J. Antibiot.; 2013; 66, pp. 459-464. [DOI: https://dx.doi.org/10.1038/ja.2013.33]
97. Watanabe, T.; Igarashi, M.; Okajima, T.; Ishii, E.; Kino, H.; Hatano, M.; Sawa, R.; Umekita, M.; Kimura, T.; Okamoto, S. et al. Isolation and characterization of signermycin B, an antibiotic that targets the dimerization domain of histidine kinase WalK. Antimicrob. Agents. Chemother.; 2012; 56, pp. 3657-3663. [DOI: https://dx.doi.org/10.1128/AAC.06467-11] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22526318]
98. Estrela, C.; Estrela, C.R.; Hollanda, A.C.; Decurcio Dde, A.; Pécora, J.D. Influence of iodoform on antimicrobial potential of calcium hydroxide. J. Appl. Oral Sci.; 2006; 14, pp. 33-37. [DOI: https://dx.doi.org/10.1590/S1678-77572006000100007] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19089027]
99. Motiwala, M.A.; Habib, S.; Ghafoor, R.; Irfan, S. Comparison of antimicrobial efficacy of Calcipex and Metapex in endodontic treatment of chronic apical periodontitis: A randomised controlled trial study protocol. BMJ Open; 2021; 11, e048947. [DOI: https://dx.doi.org/10.1136/bmjopen-2021-048947]
100. Babalska, Z.Ł.; Korbecka-Paczkowska, M.; Karpiński, T.M. Wound Antiseptics and European Guidelines for Antiseptic Application in Wound Treatment. Pharmaceuticals; 2021; 14, 1253. [DOI: https://dx.doi.org/10.3390/ph14121253]
101. Okada, A.; Igarashi, M.; Okajima, T.; Kinoshita, N.; Umekita, M.; Sawa, R.; Inoue, K.; Watanabe, T.; Doi, A.; Martin, A. et al. Walkmycin B targets WalK (YycG), a histidine kinase essential for bacterial cell growth. J. Antibiot.; 2010; 63, pp. 89-94. [DOI: https://dx.doi.org/10.1038/ja.2009.128]
102. Kato, A.; Ueda, S.; Oshima, T.; Inukai, Y.; Okajima, T.; Igarashi, M.; Eguchi, Y.; Utsumi, R. Characterization of H-box region mutants of WalK inert to the action of waldiomycin in Bacillus subtilis. J. Gen. Appl. Microbiol.; 2017; 63, pp. 212-221. [DOI: https://dx.doi.org/10.2323/jgam.2016.10.007]
103. Kitayama, T.; Iwabuchi, R.; Minagawa, S.; Sawada, S.; Okumura, R.; Hoshino, K.; Cappiello, J.; Utsumi, R. Synthesis of a novel inhibitor against MRSA and VRE: Preparation from zerumbone ring opening material showing histidine-kinase inhibition. Bioorg. Med. Chem. Lett.; 2007; 17, pp. 1098-1101. [DOI: https://dx.doi.org/10.1016/j.bmcl.2006.11.015] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17157007]
104. Watanabe, T.; Hashimoto, Y.; Yamamoto, K.; Hirao, K.; Ishihama, A.; Hino, M.; Utsumi, R. Isolation and characterization of inhibitors of the essential histidine kinase, YycG in Bacillus subtilis and Staphylococcus aureus. J. Antibiot.; 2003; 56, pp. 1045-1052. [DOI: https://dx.doi.org/10.7164/antibiotics.56.1045] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15015732]
105. Lin, Y.C.; Wu, C.Y.; Huang, H.T.; Lu, M.K.; Hu, W.S.; Lee, K.T. Bacillus subtilis natto Derivatives Inhibit Enterococcal Biofilm Formation via Restructuring of the Cell Envelope. Front Microbiol.; 2021; 12, 785351. [DOI: https://dx.doi.org/10.3389/fmicb.2021.785351] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34956152]
106. Qin, Z.; Zhang, J.; Xu, B.; Chen, L.; Wu, Y.; Yang, X.; Shen, X.; Molin, S.; Danchin, A.; Jiang, H. et al. Structure-based discovery of inhibitors of the YycG histidine kinase: New chemical leads to combat Staphylococcus epidermidis infections. BMC Microbiol.; 2006; 6, 96. [DOI: https://dx.doi.org/10.1186/1471-2180-6-96] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17094812]
107. Liu, H.; Zhao, Y.; Zhao, D.; Gong, T.; Wu, Y.; Han, H.; Xu, T.; Peschel, A.; Han, S.; Qu, D. Antibacterial and anti-biofilm activities of thiazolidione derivatives against clinical staphylococcus strains. Emerg. Microbes Infect.; 2015; 4, e1. [DOI: https://dx.doi.org/10.1038/emi.2015.17]
108. Chen, Z.; Xiong, Y.; Tang, Y.; Zhao, Y.; Chen, J.; Zheng, J.; Wu, Y.; Deng, Q.; Qu, D.; Yu, Z. In vitro activities of thiazolidione derivatives combined with daptomycin against clinical Enterococcus faecium strains. BMC Microbiol.; 2022; 22, 16. [DOI: https://dx.doi.org/10.1186/s12866-021-02423-8]
109. Deng, X.; Zhang, C.; Chen, J.; Shi, Y.; Ma, X.; Wang, Y.; Wang, Z.; Yu, Z.; Zheng, J.; Chen, Z. Antibacterial and anti-biofilm activities of histidine kinase YycG inhibitors against Streptococcus agalactiae. J. Antibiot.; 2021; 74, pp. 874-883. [DOI: https://dx.doi.org/10.1038/s41429-021-00475-6]
110. Furuta, E.; Yamamoto, K.; Tatebe, D.; Watabe, K.; Kitayama, T.; Utsumi, R. Targeting protein homodimerization: A novel drug discovery system. FEBS Lett.; 2005; 579, pp. 2065-2070. [DOI: https://dx.doi.org/10.1016/j.febslet.2005.02.056]
111. Dhuri, K.; Bechtold, C.; Quijano, E.; Pham, H.; Gupta, A.; Vikram, A.; Bahal, R. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med.; 2020; 9, 2004. [DOI: https://dx.doi.org/10.3390/jcm9062004]
112. Wu, S.; Liu, Y.; Lei, L.; Zhang, H. Nanographene oxides carrying antisense walR RNA regulates the Enterococcus faecalis biofilm formation and its susceptibility to chlorhexidine. Lett. Appl. Microbiol.; 2020; 71, pp. 451-458. [DOI: https://dx.doi.org/10.1111/lam.13354]
113. Wu, S.; Liu, Y.; Zhang, H.; Lei, L. Nano-graphene oxide with antisense walR RNA inhibits the pathogenicity of Enterococcus faecalis in periapical periodontitis. J. Dent. Sci.; 2020; 15, pp. 65-74. [DOI: https://dx.doi.org/10.1016/j.jds.2019.09.006] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32257002]
114. Moryl, M.; Palatyńska-Ulatowska, A.; Maszewska, A.; Grzejdziak, I.; Dias de Oliveira, S.; Pradebon, M.C.; Steier, L.; Różalski, A.; Poli de Figueiredo, J.A. Benefits and Challenges of the Use of Two Novel vB_Efa29212_2e and vB_Efa29212_3e Bacteriophages in Biocontrol of the Root Canal Enterococcus faecalis Infections. J. Clin. Med.; 2022; 11, 6494. [DOI: https://dx.doi.org/10.3390/jcm11216494] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36362722]
115. Kortright, K.E.; Chan, B.K.; Koff, J.L.; Turner, P.E. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Cell Host Microbe; 2019; 25, pp. 219-232. [DOI: https://dx.doi.org/10.1016/j.chom.2019.01.014]
116. Merril, C.R.; Biswas, B.; Carlton, R.; Jensen, N.C.; Creed, G.J.; Zullo, S.; Adhya, S. Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA; 1996; 93, pp. 3188-3192. [DOI: https://dx.doi.org/10.1073/pnas.93.8.3188]
117. Kim, K.P.; Cha, J.D.; Jang, E.H.; Klumpp, J.; Hagens, S.; Hardt, W.D.; Lee, K.Y.; Loessner, M.J. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol.; 2008; 1, pp. 247-257. [DOI: https://dx.doi.org/10.1111/j.1751-7915.2008.00028.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21261844]
118. Lu, T.K.; Collins, J.J. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. USA; 2007; 104, pp. 11197-11202. [DOI: https://dx.doi.org/10.1073/pnas.0704624104] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17592147]
119. Beaber, J.W.; Hochhut, B.; Waldor, M.K. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature; 2004; 427, pp. 72-74. [DOI: https://dx.doi.org/10.1038/nature02241]
120. Chatterjee, A.; Johnson, C.N.; Luong, P.; Hullahalli, K.; McBride, S.W.; Schubert, A.M.; Palmer, K.L.; Carlson, P.E., Jr.; Duerkop, B.A. Bacteriophage Resistance Alters Antibiotic-Mediated Intestinal Expansion of Enterococci. infect. Immun.; 2019; 87, e00085-19. [DOI: https://dx.doi.org/10.1128/IAI.00085-19]
121. Duerkop, B.A.; Huo, W.; Bhardwaj, P.; Palmer, K.L.; Hooper, L.V. Molecular Basis for Lytic Bacteriophage Resistance in Enterococci. mBio; 2016; 7, e01304-16. [DOI: https://dx.doi.org/10.1128/mBio.01304-16]
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
Enterococcus faecalis (E. faecalis) is a Gram-positive, facultative anaerobic bacterium that is highly adaptable to its environment. In humans, it can cause serious infections with biofilm formation. With increasing attention on its health threat, prevention and control of biofilm formation in E. faecalis have been observed. Many factors including polysaccharides as well as autolysis, proteases, and eDNA regulate biofilm formation. Those contributors are regulated by several important regulatory systems involving the two-component signal transduction system (TCS) for its adaptation to the environment. Highly conserved WalRK as one of 17 TCSs is the only essential TCS in E. faecalis. In addition to biofilm formation, various metabolisms, including cell wall construction, drug resistance, as well as interactions among regulatory systems and resistance to the host immune system, can be modulated by the WalRK system. Therefore, WalRK has been identified as a key target for E. faecalis infection control. In the present review, the regulation of WalRK on E. faecalis pathogenesis and associated therapeutic strategies are demonstrated.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Orthopedic Research Institute, Department of Orthopedics, West China Hospital, Sichuan University, Chengdu 610017, China
2 West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610017, China
3 West China Hospital of Stomatology, Sichuan University, Chengdu 610017, China